Neumora Therapeutics (NMRA) Asset Writedowns and Impairment (2024 - 2025)
Neumora Therapeutics' (NMRA) quarterly Asset Writedowns and Impairment came in at $217000.0 in Q4 2025, up 1133.33% year-on-year from $17594.6 in Q4 2024, and up 1133.33% quarter-over-quarter from -$21000.0 in Q4 2024.
Neumora Therapeutics (NMRA) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Neumora Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $217000.0 for Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment rose 1133.33% year-over-year to $217000.0 in Q4 2025; TTM through Dec 2025 was $217000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $595000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment grew to $217000.0 in Q4 2025 per NMRA's latest filing, from -$21000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $217000.0 in Q4 2025 and bottomed at -$21000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Neumora Therapeutics | 280.60 Mn | 280.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 217,000.00 |
| Dec 31, 2025 | 217,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Sep 30, 2024 | 21,000.00 |